Glenmede Trust’s Revance Therapeutics, Inc. RVNC Stock Holding History

Glenmede Trust’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-15,774	Closed	-$291K	–	1359
2022 Q4	$291K	Buy	15,774 +4,641	+42%	+$106K	﹤0.01%	994
2022 Q3	$300K	Buy	+11,133	New	+$226K	﹤0.01%	961
2020 Q4	–	Sell	-1,961	Closed	-$49K	–	2327
2020 Q3	$49K	Buy	1,961 +61	+3%	+$1.6K	﹤0.01%	1340
2020 Q2	$46K	Sell	1,900 -1,482	-44%	-$29.3K	﹤0.01%	1338
2020 Q1	$54K	Hold	3,382	–	–	﹤0.01%	1659
2019 Q4	$54K	Sell	3,382 -68	-2%	-$1.05K	﹤0.01%	1659
2019 Q3	$44	Hold	3,450	–	–	﹤0.01%	1720
2019 Q2	$44	Buy	3,450 +3,340	+3,036%	+$42.1K	﹤0.01%	1740
2019 Q1	$1	Hold	110	–	–	﹤0.01%	2977
2018 Q4	$2	Buy	+110	New	+$2.42K	﹤0.01%	2803

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Glenmede Trust's RVNC Position: Q1 2023 in Review

Glenmede Trust sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2023, closing a stake of 15,774 shares — an estimated $291K sold.

Glenmede Trust first reported a position in RVNC in Q4 2018 and held it in 10 quarters. The position peaked at $300K in Q3 2022. 216 funds tracked by Wall St. Rank hold RVNC as of Q1 2023.

Glenmede Trust reported no remaining Revance Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
Glenmede Trust sold 15,774 Revance Therapeutics, Inc. shares in Q1 2023, an estimated $291K.
Glenmede Trust first reported a position in Revance Therapeutics, Inc. in Q4 2018 and held it in 10 quarters.
Glenmede Trust's Revance Therapeutics, Inc. position peaked at $300K in Q3 2022.
216 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2023.

Based on Glenmede Trust's 13F filing for Q1 2023, filed 15 May 2023.